Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

by WHITE, Harvey D , TSE, Hung-Fat , HONG CHEN , DENCHEV, Stefan , NICOLAU, José C , HUSTED, Steen , MOHLER, Emile R , AVEZUM, Alvaro , PEDERSEN, Terje R , ELISAF, Moses , LONN, Eva , HELD, Claes , RAMOS-CORRALES, Marco A , JUNREN ZHU , DALBY, Anthony J , TARKA, Elizabeth , VIIGIMAA, Margus , ARDISSINO, Diego , SWART, Henk P , WOLFGANG KOENIG , DE WINTER, Robbert J , WEISS, Robert , DAVIES, Richard Y , PELLA, Daniel , DANCHIN, Nicolas , TERAMOTO, Tamio , HOCHMAN, Judith S , VINEREANU, Dragos , WATSON, David , LOPEZ-SENDON, José , BRYCE, Alfonso , CHEN, Ming-Fong , BUDAJ, Andrzej , ARMSTRONG, Paul W , PARKHOMENKO, Alexander , SRITARA, Piyamitr , GOUDEV, Assen R , SINNAEVE, Peter , RUDA, Mikhail , SMITH, Peter , SEREG, Mátyás , STEG, P. Gabriel , HARRINGTON, Robert A , BROWN, Rebekkah , CANNON, Christopher P , AYLWARD, Philip E , STEWART, Ralph , GRANGER, Christopher B , FLATHER, Marcus D , CORBALAN, Ramon , DIAZ, Rafael , SIDDIQUE, Saulat , KIM, Hyo-Soo , WEAVER, W. Douglas , PAIS, Prem , GRINFELD, Liliana , SY, Rody G , LINHART, Ales , MANOLIS, Athanasios J

in Aged / Angina / Arteriosclerosis / Assaigs clínics de medicaments / Benzaldehydes - administration & dosage / Benzaldehydes - adverse effects / Biological and medical sciences / Cardiology. Vascular system / Cardiovascular disease / Cardiovascular diseases / Cerebral infarction / Clinical trials / Coronary artery disease / Coronary Artery Disease - complications / Coronary Artery Disease - drug therapy / Coronary Disease - drug therapy / Coronary Disease - mortality / Coronary diseases / Coronary heart disease / Death / Double-Blind Method / Drug testing / Drug therapy / Female / Follow-Up Studies / General aspects / Heart / Heart diseases / Humans / Infart de miocardi / Ischemia / Kaplan-Meier Estimate / Malalties cardiovasculars / Malalties coronàries / Male / Medical sciences / Middle Aged / Myocardial infarction / Myocardial Infarction - prevention & control / Myocardial ischemia / Oximes - administration & dosage / Oximes - adverse effects / Phospholipase A2 / Phospholipase A2 Inhibitors - administration & dosage / Phospholipase A2 Inhibitors - adverse effects / Plaques / Plasma levels / Preventive medicine / Stroke - prevention & control / Treatment Failure

2014

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

2014

Confirm

Do you wish to request the book?

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

2014

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

WHITE, Harvey D,

TSE, Hung-Fat,

HONG CHEN,

DENCHEV, Stefan,

NICOLAU, José C,

HUSTED, Steen,

MOHLER, Emile R,

AVEZUM, Alvaro,

PEDERSEN, Terje R,

ELISAF, Moses,

LONN, Eva,

HELD, Claes,

RAMOS-CORRALES, Marco A,

JUNREN ZHU,

DALBY, Anthony J,

TARKA, Elizabeth,

VIIGIMAA, Margus,

ARDISSINO, Diego,

SWART, Henk P,

WOLFGANG KOENIG,

DE WINTER, Robbert J,

WEISS, Robert,

DAVIES, Richard Y,

PELLA, Daniel,

DANCHIN, Nicolas,

TERAMOTO, Tamio,

HOCHMAN, Judith S,

VINEREANU, Dragos,

WATSON, David,

LOPEZ-SENDON, José,

BRYCE, Alfonso,

CHEN, Ming-Fong,

BUDAJ, Andrzej,

ARMSTRONG, Paul W,

PARKHOMENKO, Alexander,

SRITARA, Piyamitr,

GOUDEV, Assen R,

SINNAEVE, Peter,

RUDA, Mikhail,

SMITH, Peter,

SEREG, Mátyás,

STEG, P. Gabriel,

HARRINGTON, Robert A,

BROWN, Rebekkah,

CANNON, Christopher P,

AYLWARD, Philip E,

STEWART, Ralph,

GRANGER, Christopher B,

FLATHER, Marcus D,

CORBALAN, Ramon,

DIAZ, Rafael,

SIDDIQUE, Saulat,

KIM, Hyo-Soo,

WEAVER, W. Douglas,

PAIS, Prem,

GRINFELD, Liliana,

SY, Rody G,

LINHART, Ales,

MANOLIS, Athanasios J

2014

Overview

Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease. Darapladib did not significantly reduce the risk of cardiovascular death, myocardial infarction, or stroke. Atherosclerotic lesions in humans — in particular, vulnerable 1 and ruptured plaques — are characterized by inflammatory activity and a high expression of lipoprotein-associated phospholipase A 2 . 2 , 3 In atherosclerotic plaques, lipoprotein-associated phospholipase A 2 increases the production of proinflammatory and proapoptotic mediators. 4 – 8 In a meta-analysis of individual records from 79,036 participants in 32 prospective studies, there was a continuous association between lipoprotein-associated phospholipase A 2 activity and the risk of coronary heart disease, with a relative increase in risk of 1.10 (95% confidence interval [CI], 1.05 to 1.16) for each 1-SD increase in lipoprotein-associated phospholipase A 2 activity, . . .

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Aged

/ Angina

/ Arteriosclerosis

/ Assaigs clínics de medicaments

/ Benzaldehydes - administration & dosage

/ Benzaldehydes - adverse effects

/ Biological and medical sciences